%	O
%	O
TITLE	O

Epidemiologic	O
associations	O
of	O
HPV	O
-	O
positive	O
oropharyngeal	O
cancer	O
and	O
(	O
pre	O
)	O
cancerous	O
cervical	O
lesions	O
.	O

%	O
%	O
ABSTRACT	O

Human	O
papillomavirus	O
(	O
HPV	O
)	O
-	O
induced	O
oropharyngeal	O
squamous	O
cell	O
carcinoma	O
(	O
OPSCC	O
)	O
remains	O
increasing	O
worldwide	O
.	O

We	O
aimed	O
to	O
investigate	O
if	O
the	O
HPV	O
-	O
prevalence	B-Incidence_or_Prevalence
of	O
OPSCC	O
in	O
the	O
Netherlands	B-Study_Location
is	O
rising	O
as	O
well	O
,	O
also	O
in	O
female	O
patients	O
.	O

In	O
addition	O
,	O
we	O
evaluated	O
the	O
association	O
between	O
HPV	O
-	O
positive	O
OPSCC	O
and	O
suspicious	O
Pap	O
results	O
of	O
the	O
cervix	O
in	O
these	O
female	O
patients	O
.	O

Patients	B-Study_Cohort
with	I-Study_Cohort
OPSCC	I-Study_Cohort
treated	O
in	O
the	O
period	O
2000	B-Study_Time
-	I-Study_Time
2015	I-Study_Time
at	O
the	O
VU	O
University	O
Medical	O
Center	O
Amsterdam	O
,	O
were	O
included	O
(	O
nâ€‰=â€‰926	O
)	O
.	O

The	O
presence	O
of	O
an	O
oncogenic	O
HPV	O
infection	O
was	O
determined	O
by	O
p16	O
-	O
immunostaining	O
,	O
followed	O
by	O
a	O
high	O
-	O
risk	O
HPV	O
general	O
primer	O
5	O
+	O
/	O
6	O
+	O
DNA	B-HPV_Lab_Technique
PCR	I-HPV_Lab_Technique
on	O
the	O
p16	O
-	O
immunopositive	O
cases	O
.	O

A	O
review	O
of	O
pathology	O
reports	O
in	O
all	O
female	O
patients	O
(	O
nâ€‰=â€‰305	O
)	O
was	O
undertaken	O
to	O
identify	O
cytological	O
signs	O
of	O
HPV	O
-	O
related	O
(	O
pre	O
)	O
cancer	O
of	O
the	O
cervix	O
.	O

In	O
total	O
281	O
of	O
926	O
(	O
30	O
.	O
3	O
%	O
)	O
OPSCCs	O
were	O
HPV	O
-	O
positive	O
.	O

Moreover	O
,	O
a	O
significant	O
increase	O
in	O
the	O
prevalence	B-Incidence_or_Prevalence
of	O
HPV	O
-	O
positive	O
OPSCCs	O
was	O
observed	O
from	O
14	O
.	O
0	O
%	O
in	O
2000	O
to	O
48	O
.	O
1	O
%	O
in	O
2015	O
(	O
pâ€‰	O
<	O
â€‰0	O
.	O
001	O
)	O
.	O

Among	O
the	O
female	O
patients	O
with	O
an	O
HPV	O
-	O
positive	O
OPSSC	O
(	O
nâ€‰=â€‰70	O
)	O
,	O
the	O
results	O
of	O
cervical	O
smears	O
were	O
available	O
in	O
56	O
of	O
70	O
patients	O
(	O
80	O
.	O
0	O
%	O
)	O
.	O

Of	O
the	O
female	O
patients	O
with	O
HPV	O
-	O
positive	O
OPSCC	O
,	O
9	O
of	O
56	O
(	O
16	O
.	O
1	O
%	O
)	O
patients	O
had	O
a	O
vaginal	O
cuff	O
Papanicolaou	O
(	O
Pap	O
)	O
test	O
â‰¥3b	O
in	O
their	O
medical	O
history	O
compared	O
to	O
7	O
of	O
168	O
(	O
4	O
.	O
2	O
%	O
)	O
in	O
the	O
HPV	O
-	O
negative	O
group	O
(	O
pâ€‰=â€‰0	O
.	O
003	O
)	O
.	O

In	O
conclusion	O
,	O
a	O
continuous	O
increase	O
in	O
the	O
HPV	O
-	O
attributable	O
fraction	O
of	O
OPSCC	O
was	O
demonstrated	O
in	O
the	O
period	O
2000	O
-	O
2015	O
in	O
the	O
Amsterdam	O
region	O
.	O

HPV	O
-	O
positive	O
OPSCC	O
has	O
a	O
significant	O
association	O
with	O
a	O
history	O
of	O
suspicious	O
Pap	O
results	O
of	O
the	O
cervix	O
in	O
female	O
patients	O
.	O

%	O
%	O
MATERIALS	O
AND	O
METHODS	O

Study	O
design	O

Our	O
study	O
included	O
all	B-Study_Cohort
patients	I-Study_Cohort
with	I-Study_Cohort
OPSCC	I-Study_Cohort
that	O
were	O
treated	O
at	O
VU	O
University	O
Medical	O
Center	O
(	O
VUmc	O
)	O
in	O
the	O
period	O
2000–2015	B-Study_Time
(	O
n	O
5	O
947	O
)	O
.	O

In	O
total	O
,	O
926	O
of	O
947	O
biopsies	B-HPV_Sample_Type
could	O
be	O
obtained	O
from	O
the	O
pathology	O
archives	O
.	O

Data	O
from	O
2000	O
to	O
2006	O
were	O
previously	O
published	O
,	O
data	O
from	O
the	O
years	O
2007	O
to	O
2015	O
have	O
been	O
added	O
.	O
24	O
The	O
patients	O
were	O
identi	O
-	O
ﬁed	O
through	O
the	O
Netherlands	B-Study_Location
Comprehensive	O
Cancer	O
Organisation	O
.	O

Patient	O
characteristics	O
,	O
information	O
on	O
smoking	O
behavior	O
(	O
one	O
pack	O
year	O
5	O
20	O
cigarettes	O
a	O
day	O
during	O
one	O
year	O
)	O
and	O
alcohol	O
consumption	O
(	O
one	O
unit	O
year	O
5	O
one	O
alcohol	O
-	O
containing	O
drink	O
a	O
day	O
during	O
one	O
year	O
)	O
as	O
well	O
as	O
clinical	O
outcome	O
were	O
obtained	O
from	O
the	O
patient	O
ﬁles	O
.	O

The	O
presence	O
of	O
HPV	O
was	O
detected	O
using	O
pre	O
-	O
treatment	O
formalin	B-HPV_Sample_Type
-	I-HPV_Sample_Type
ﬁxed	I-HPV_Sample_Type
,	I-HPV_Sample_Type
parafﬁn	I-HPV_Sample_Type
-	I-HPV_Sample_Type
embedded	I-HPV_Sample_Type
(	I-HPV_Sample_Type
FFPE	I-HPV_Sample_Type
)	I-HPV_Sample_Type
biopsies	I-HPV_Sample_Type
.	I-HPV_Sample_Type

Eligible	O
samples	O
included	O
histopathologically	O
conﬁrmed	O
invasive	O
squamous	O
cell	O
carcinoma	O
of	O
the	O
oropharynx	O
(	O
International	O
classiﬁcation	O
of	O
diseases	O
for	O
Oncology	O
,	O
[	O
ICD	O
-	O
10	O
]	O
codes	O
C019	O
,	O
C051	O
,	O
C052	O
,	O
C090	O
-	O
C099	O
and	O
C100	O
-	O
C109	O
)	O
.	O

Approval	O
for	O
this	O
retrospective	O
study	O
was	O
obtained	O
from	O
the	O
Institutional	O
Review	O
Board	O
and	O
use	O
of	O
tissue	B-HPV_Sample_Type
specimen	I-HPV_Sample_Type
and	O
patient	O
data	O
adheres	O
to	O
the	O
guidelines	O
for	O
approved	O
use	O
of	O
human	O
tissue	O
(	O
.	O

All	B-Study_Cohort
female	I-Study_Cohort
patients	I-Study_Cohort
with	I-Study_Cohort
OPSCC	I-Study_Cohort
(	O
n	O
5	O
308	O
)	O
were	O
selected	O
.	O

The	O
presence	O
of	O
(	O
pre	O
)	O
cancerous	O
cervical	O
lesions	O
,	O
as	O
deﬁned	O
by	O
abnormal	O
Pap	O
smears	O
,	O
was	O
determined	O
by	O
the	O
pathologist	O
(	O
EB	O
)	O
through	O
a	O
search	O
in	O
the	O
national	O
pathology	O
database	O

(	O
PALGA	O
)	O
.	O

Cervical	O
lesions	O
were	O
divided	O
into	O
categories	O
according	O
to	O
the	O
Papanicolaou	O
classiﬁcation	O
which	O
is	O
con	O
-	O
nected	O
to	O
the	O
KOPAC	O
-	O
B	O
encryption	O
.	O
25	O
,	O
26	O

HPV	O
testing	O

Parafﬁn	B-HPV_Sample_Type
sections	I-HPV_Sample_Type
were	O
prepared	O
according	O
to	O
the	O
sandwich	O
method	O
:	O
the	O
ﬁrst	O
and	O
last	O
sections	O
were	O
stained	O
by	O
haematox	O
-	O
ylin	O
and	O
eosin	O
to	O
check	O
for	O
tumor	O
presence	O
.	O

Sections	O
of	O
3	O
mm	O
were	O
made	O
for	O
p16	O
-	O
immunostaining	O
.	O

A	O
total	O
of	O
four	O
sections	O
of	O
10	O
mm	O
were	O
used	O
for	O
DNA	O
isolation	O
and	O
HPV	O
DNA	O
detec	O
-	O
tion	O
.	O

Precautions	O
taken	O
to	O
avoid	O
cross	O
-	O
contamination	O
,	O
have	O
been	O
described	O
before	O
.	O
12	O

P16	O
-	O
immunohistochemistry	O
(	O
p16	O
-	O
IHC	O
)	O
was	O
performed	O
on	O
FFPE	O
tissue	O
sections	O
.	O

After	O
pre	O
-	O
treatment	O
with	O
Epitope	O
Retrieval	O
Solution	O
2	O
for	O
20	O
min	O
at	O
998C	O
,	O
sections	B-HPV_Sample_Type
were	O
incu	O
-	O
bated	O
with	O
the	O
mouse	O
monoclonal	O
antibody	O
INK4A	O
directed	O
against	O
p16INK4A	O
(	O
CINtec	O
Histology	O
Kit	O
,	O
Ventana	O
,	O
Tucson	O
,	O
USA	O
)	O
on	O
a	O
BONDmax	O
(	O
Leica	O
,	O
Amsterdam	O
,	O
the	O
Netherlands	O
)	O
automated	O
platform	O
.	O

As	O
a	O
negative	O
control	O
,	O
a	O
monoclonal	O
mouse	O
antibody	O
against	O
Rat	O
oxytocin	O
-	O
related	O
neurophysin	O
was	O
used	O
.	O

Two	O
independent	O
observers	O
performed	O
evaluation	O
of	O
the	O
slides	O
and	O
consensus	O
was	O
achieved	O
in	O
all	O
cases	O
.	O

Scoring	O
of	O
the	O
slides	O
was	O
performed	O
as	O
described	O
before	O
.	O
12	O

The	B-HPV_Lab_Technique
GP51	I-HPV_Lab_Technique
/	I-HPV_Lab_Technique
61	I-HPV_Lab_Technique
-	I-HPV_Lab_Technique
PCR	I-HPV_Lab_Technique
with	I-HPV_Lab_Technique
enzyme	I-HPV_Lab_Technique
-	I-HPV_Lab_Technique
immuno	I-HPV_Lab_Technique
-	I-HPV_Lab_Technique
assay	I-HPV_Lab_Technique
(	I-HPV_Lab_Technique
EIA	I-HPV_Lab_Technique
)	I-HPV_Lab_Technique
read	O
-	O
out	O
was	O
used	O
for	O
DNA	O
detection	O
of	O
14	O
high	O
-	O
risk	O
HPV	O
types	O
(	O
HPV	O
16	O
,	O
18	O
,	O
31	O
,	O
33	O
,	O
35	O
,	O
39	O
,	O
45	O
,	O
51	O
,	O
52	O
,	O
56	O
,	O
58	O
,	O
59	O
,	O
66	O

and	O
68	O
)	O
.	O
27	O

Subsequent	O
genotyping	O
of	O
the	O
virus	O
was	O
performed	O
by	O
bead	O
-	O
based	O
array	O
on	O
the	O
Luminex	O
platform	O
.	O
28	O
Sample	O
quality	O
after	O
DNA	O
extraction	O
was	O
controlled	O
by	O
b	O
-	O
globin	O
PCR	O
(	O
amplicon	O
size	O
100	O
bp	O
)	O
.	O
29	O
All	O
GP51	B-HPV_Lab_Technique
/	I-HPV_Lab_Technique
61	I-HPV_Lab_Technique
negative	I-HPV_Lab_Technique
PCR	I-HPV_Lab_Technique
results	O
had	O
to	O
be	O
positive	O
for	O
the	O
b	O
-	O
globin	O
PCR	B-HPV_Lab_Technique
.	O

Otherwise	O
the	O
sam	O
-	O
ple	O
was	O
considered	O
as	O
non	O
-	O
diagnostic	O
in	O
the	O
analysis	O
,	O
but	O
this	O
did	O
not	O
occur	O
.	O

When	O
p16	O
-	O
immunostaining	O
was	O
positive	O
,	O
but	O
GP	B-HPV_Lab_Technique
51	I-HPV_Lab_Technique
/	I-HPV_Lab_Technique
61	I-HPV_Lab_Technique
PCR	I-HPV_Lab_Technique
was	O
negative	O
,	O
type	O
-	O
speciﬁc	O
PCR	B-HPV_Lab_Technique
for	O
HPV16	O
was	O
performed	O
in	O
addition	O
using	O
primers	O
in	O
the	O
E7	O
gene	O
to	O
exclude	O
false	O
-	O
negative	O
ﬁndings	O
by	O
viral	O
integration	O
.	O
30	O

Statistical	O
Methods	O

The	O
Pearson	O
v2	O
test	O
(	O
v2	O
)	O
and	O
the	O
Fisher’s	O
exact	O
test	O
were	O
used	O
to	O
analyze	O
the	O
distribution	O
of	O
the	O
different	O
Pap	B-HPV_Sample_Type
smears	I-HPV_Sample_Type
in	O
female	O
patients	O
with	O
HPV	O
-	O
positive	O
and	O
HPV	O
-	O
negative	O
OPSCC	O
.	O

Also	O
differences	O
in	O
patient	O
characteristics	O
between	O
HPV	O
-	O
positive	O
and	O
HPV	O
-	O
negative	O
cases	O
were	O
assessed	O
using	O
the	O
Pearson	O
v2	O
test	O
(	O
v2	O
)	O
.	O

The	O
Student’s	O
t	O
-	O
test	O
was	O
used	O
to	O

Table	O
1	O
.	O

Patient	O
and	O
tumor	O
characteristics	O
in	O
relation	O
to	O
HPV	O
-	O
status	O
in	O
patients	O
with	O
OPSCC	O

Abbreviations	O
:	O
Oropharynx	O
nos	O
:	O
oropharynx	O
not	O
otherwise	O
specified	O
;	O
Nx	O
:	O
unknown	O
N	O
-	O
stage	O
;	O
Tx	O
:	O
unknown	O
T	O
-	O
stage	O
.	O

1Independent	O
t	O
-	O
test	O
.	O

2v2	O
test	O
.	O

*	O
p	O
-	O
value	O
of	O
HPV	O
-	O
positive	O
group	O
compared	O
to	O
HPV	O
-	O
negative	O
group	O

compare	O
the	O
mean	O
age	O
between	O
HPV	O
-	O
positive	O
and	O
HPV	O
-	O
negative	O
cases	O
.	O

The	O
Cochran	O
-	O
Armitage	O
test	O
for	O
trend	O
was	O
per	O
-	O
formed	O
to	O
compare	O
proportions	O
of	O
HPV	O
DNA	O
-	O
positive	O
sam	O
-	O
ples	O
across	O
the	O
different	O
time	O
periods	O
.	O

Statistical	O
analysis	O
was	O

performed	O
using	O
SPSS	O
(	O
version	O
15	O
,	O
SPSS	O
,	O
Inc	O
.	O
,	O
Chicago	O
,	O
IL	O
)	O
.	O

A	O
p	O
-	O
value	O
of	O
0	O
.	O
05	O
was	O
considered	O
to	O
indicate	O
statistical	O
signiﬁcance	O
.	O

